In Vivo Confirmation of the Role of Statins in Reducing Nitric Oxide and C-Reactive Protein Levels in Peripheral Arterial Disease

European Journal of Vascular and Endovascular Surgery

Volumn 37, Issue 4, 2009, Pages 443-447

  Martinez Aguilar E ^a   De Haro Miralles, J ^a   Florez Gonzalez A ^a   Varela Casariego, C ^a   Bleda Moreno, S ^a   Acin Garcia F ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

C reactive protein; Endothelial dysfunction; Inflammatory processes; Nitric oxide; Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; NITRITE;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CLAUDICATION; CLINICAL TRIAL; COLORIMETRY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CHOLESTEROL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NITRITES; PERIPHERAL VASCULAR DISEASES; PROSPECTIVE STUDIES; PYRROLES; TRIGLYCERIDES;

EID: 61849160407     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2008.12.009     Document Type: Article

References (36)

1. Ignarro L.J., Cirino G., Casini A., and Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 34 (1999) 879-886
2. Harrison D.G. Cellular and molecular mechanism of endothelial cell dysfunction. J Clin Invest 100 (1997) 2153-2157
3. Kalinowski L., Dobrucki L.W., Brovkovych V., and Malinski T. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 105 (2002) 933-938
4. Kalinowski L., and Malinski T. Endothelial NADH/NADPH-dependent enzymatic sources of superoxide production: relationship to endothelial dysfunction. Acta Biochim Pol 51 (2004) 459-469
5. De Haro J, Martínez-Aguilar E, Flórez A, Varela C, March JR, Acín F. Nitric oxide: the hinge between endothelial dysfunction and inflammation in peripheral arterial occlusive disease patients. Interact CardioVasc Thorac Surg 2008;7 (Suppl. 1):S1.
6. Pepys M.B., and Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest 111 (2003) 1805-1812
7. De Haro J., Acin F., Lopez-Quintana A., Medina F.J., Martinez-Aguilar E., Florez A., et al. Direct association between C-reactive protein serum levels and endothelial dysfunction in patients with claudication. Eur J Vasc Endovasc Surg 35 4 (2008) 480-486
8. Barbato J.E., and Tzeng E. Nitric oxide and arterial disease. J Vasc Surg 40 (2004) 187-193
9. Miyoshi T., Li Y., Shih D.M., Wang X., Laubach V.E., Matsumoto A.H., et al. Deficiency of inducible NO synthase reduces advanced but not early atherosclerosis in apolipoprotein E-deficient mice. Life Sci 79 (2006) 525-531
10. Heeba G., Hassan M.K.A., Khalifa M., and Malinski T. Adverse balance of nitric oxide/peroxinitrite in the dysfunctional endothelium can be reversed by statins. J Cardiovasc Pharmacol 50 (2007) 391-398
11. Hattori Y., Nakanishi N., Akimoto K., Yoshida M., and Kasai K. HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol 23 (2003) 176-182
12. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
13. Rikitake Y., Kawashima S., Takeshita S., Yamashita T., Azumi H., Yasuhara M., et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154 (2001) 87-96
14. Ridker P., Rifai N., Pfeffer M.A., Sacks F., and Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100 (1999) 230-235
15. Newman A.B., Shemanski L., Manolio T.A., Cushman M., Mittelmark M., Polak J.F., et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 19 (1999) 538-545
16. Verdecchia P., and Angeli F. The seventh report of the Joint National Committee on the prevention, detection, evaluation and treatment of high blood pressure: the weapons are ready. Rev Esp Cardiol 56 (2003) 843-847
17. National Heart, Lung, and Blood Institute. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III, or ATP III). Available from:. [accessed 25.02.2006]
18. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 24 (2001) 5-20
19. Ferrer R., and Hernández-Jara J. Chronic renal insufficiency. I: Definition, clinical course stages, progression mechanisms, etiology, and diagnostic criteria. Nefrologia 21 (2001) 18-20
20. Kleinbongard P., Rassaf T., Dejam A., Kerber S., and Kelm M. Griess method for nitrite measurement of aqueous and protein containing sample. Methods Enzymol 359 (2002) 158-168
21. Eda S., Kaufmann J., Roos W., and Pohl S. Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range. J Clin Lab Anal 12 (1998) 137-144
22. Shimada K., Mokuno H., Matsunaga E., Miyazaki T., Sumiyoshi K., Miyauchi K., et al. Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Diabetes Care 27 (2004) 843-844
23. Liao J.K., Shin W.S., Lee W.Y., and Clark S.L. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 270 (1995) 319-324
24. Dart A.M., and Chin-Dusting J.P.F. Lipids and the endothelium. Cardiovasc Res 43 (1999) 308-322
25. Williams J.K., Sukhova G.K., Herrington D.M., and Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 31 (1998) 684-691
26. Rosenson R.S., and Tangney C.C. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA 279 (1998) 1643-1650
27. Davignon J., and Laaksonen R. Low-density lipoprotein-independent effects of stains. Curr Opin Lipidol 10 (1999) 543-559
28. Gokce N., Keaney Jr. J.F., Hunter L.M., Watkins M.T., Nedeljkovic Z.S., Menzoian J.O., et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 41 (2003) 1769-1775
29. Wagner A.H., Kohler T., Ruckschloss, Just I., and Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20 (2000) 61-69
30. Bevers L.M., Braam B., Post J.A., van Zonneveld A.J., Rabelink T.J., Koomans H.A., et al. Tetrahydrobiopterin, but not L-arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase. Hypertension 47 (2006) 87-94
31. Brevetti G., Silvestro A., Di Giacomo S., Bucur R., Di Donato A., Schiano V., et al. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerosis burden. J Vasc Surg 38 (2003) 374-379
32. Kobayashi S., Inoue N., Ohashi Y., Terashima M., Matsui K., Mori T., et al. Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of CRP. Arterioscler Thromb Vasc Biol 23 (2003) 1398-1404
33. Singh U., Devaraj S., Vasquez-Vivar J., and Jialal I. C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol 43 (2007) 780-791
34. Clapp B.R., Hirschfield G.M., Storry C., Gallimore J.R., Stidwill R.P., Singer M., et al. Inflammation and endothelial function. Direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation 111 (2005) 1530-1536
35. Suárez C., Cairols M., Castillo J., Esmatjes E., Sala J., Llobet X., et al., In behalf of investigators at REACH Registry Spain. Risk factor control and treatment of atherothrombosis. Spain REACH Registry. Med Clin (Barc) 129 12 (2007) 446-450
36. Kleinbongard P., Dejam A., Lauer T., Rassaf T., Schindler A., and Picker O. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 35 (2003) 1551-1559